TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Stock
Certificat
DE000SF7UUX5
| Market Closed - Deutsche Boerse AG 15:42:19 2024-06-19 EDT | ||
| 24.69 EUR | -1.63% |
|
| Current month | +4.09% | ||
| 1 month | +8.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 24.69 | -1.63% |
| 24-06-18 | 25.1 | -2.60% |
| 24-06-17 | 25.77 | -2.86% |
| 24-06-14 | 26.53 | +1.22% |
| 24-06-13 | 26.21 | +1.79% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 03:42 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7UUX |
| ISIN | DE000SF7UUX5 |
| Date issued | 2021-08-18 |
| Strike | 200.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.24 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.68 € |
|---|---|
| Lowest since issue | 1.21 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Certificates
- Certificat
